Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women.

By Michaela A. Pfeifer, B. Begerow, H. W. Minne, D. Nachtigall, C. Hansen. Journal of Clinical Endocrinology and Metabolism, 2001

701 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Orthopedics and Sports Medicine, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/8191c92b6ceaae882e19e9333d34de3a4c28f1b4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. M. F. Holick

In Orthopedics and Sports Medicine

1. D. Deeg
2. Marjolein Visser
3. P. Lips
4. A. Zittermann
5. M. F. Holick
6. D. Bikle

In Pathology and Forensic Medicine

1. M. F. Holick
2. AG Pittas
3. Joseph Lau
4. D. Deeg
5. Marjolein Visser
6. P. Lips
7. A. Zittermann
8. M. Demay

Citations in the corpus

• 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system (2002, methodology): “Furthermore, it has been reported that vitamin D3 supplementation reduces blood pressure in patients with essential hypertension (19, 20), and 1,25(OH)2D3 treatment reduces blood pressure, plasma renin activity, and Ang II levels in hyperparathyroidism patients (21, 22).”
• Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. (2004, background): “In clinical trials, Vitamin D treatment has been reported to reduce blood pressure in hypertensive or elderly patients [36,37].”
• Vitamin D and human health: lessons from vitamin D receptor null mice. (2008, background): “studies (596), and 1 -hydroxylated vitamin D therapy also”
• Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. (2003, background): “It is known that vitamin D supplementation increases 25-OHD and 1,25-(OH)2D3 and decreases PTH (5, 64).”
• 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. (2002, methodology): “Furthermore, it has been reported that vitamin D3 supplementation reduces blood pressure in patients with essential hypertension (19, 20), and 1,25(OH)2D3 treatment reduces blood pressure, plasma renin activity, and Ang II levels in hyperparathyroidism patients (21, 22).”
• Vitamin D in preventive medicine: are we ignoring the evidence? (2003, background): “This may explain why some improvements in fracture prevalence, muscle function and blood pressure have been achieved with daily supplements of 20mg vitamin D in combination with 1200 mg Ca/d (Chapuy et al. 1992; Pfeifer et al. 2000, 2001).”
• Systematic Review: Vitamin D and Cardiometabolic Outcomes (2010, background): “Net Change in Systolic Blood Pressure From Baseline, mm Hg –20 –10 0 10 110 130 120 140 150 Scragg et al, 1995 (27) Pfeifer et al, 2001 (30) Sugden et al, 2008 (17) Jorde et al, 2009 (22) Krause et al, 1998 (33) Margolis et al, 2008 (32) Zittermann et al, 2009 (20) Schleithoff et al, 2006 (28) Nagpa”